glp 1 drug manufacturers Personalized GLP-1 The Next Big Weight Loss
Description
Burden of heart failure and underlying causes in 195 countries and territories from 1990 to 2017
This study found a clear dose-response relationship for Cotadutide, Danuglipron, JNJ-64565111, Retatrutide, Orforglipron, and injectable Semaglutide
Robinson, P
doi: 10.1016/j.biopha.2020.110523 57 YeYZhongXLiNPanT
Enthusiasm is running high, but it's too early to start prescribing GLP-1s as a cancer-fighting treatment
Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: A position statement
